Kidney Week Educational Symposia-Accelerating Development of Therapies for APOL1-Mediated Kidney Disease

Video Transcription

Video Summary

<strong style="box-sizing: border-box; font-weight: bold; color: #000000; font-family: 'Source Sans Pro', sans-serif; font-size: 14px; white-space: normal; background-color: #ffffff;">Moderator(s):</strong><span style="color: #000000; font-family: 'Source Sans Pro', sans-serif; font-size: 14px; white-space: normal; background-color: #ffffff; float: none; display: inline;"> Itunu Owoyemi</span><br style="box-sizing: border-box; color: #000000; font-family: 'Source Sans Pro', sans-serif; font-size: 14px; white-space: normal; background-color: #ffffff;" /><br style="box-sizing: border-box; color: #000000; font-family: 'Source Sans Pro', sans-serif; font-size: 14px; white-space: normal; background-color: #ffffff;" /><strong style="box-sizing: border-box; font-weight: bold; color: #000000; font-family: 'Source Sans Pro', sans-serif; font-size: 14px; white-space: normal; background-color: #ffffff;">Presentation(s):</strong><br style="box-sizing: border-box; color: #000000; font-family: 'Source Sans Pro', sans-serif; font-size: 14px; white-space: normal; background-color: #ffffff;" />
<ul style="box-sizing: border-box; margin-top: 0px; margin-bottom: 10px; color: #000000; font-family: 'Source Sans Pro', sans-serif; font-size: 14px; white-space: normal; background-color: #ffffff;">
<li style="box-sizing: border-box;"><strong style="box-sizing: border-box; font-weight: bold;">Introduction</strong> - Itunu Owoyemi</li>
<li style="box-sizing: border-box;"><strong style="box-sizing: border-box; font-weight: bold;">Rationale, Logistics, and Implications of Screening for AMKD</strong> - Barry Freedman</li>
<li style="box-sizing: border-box;"><strong style="box-sizing: border-box; font-weight: bold;">Current Clinical Trials and Design Considerations in Novel AMKD Therapies</strong> - Titilayo Ilori</li>
</ul>
<br /><em style="box-sizing: border-box; color: #000000; font-family: 'Source Sans Pro', sans-serif; font-size: 14px; white-space: normal; background-color: #ffffff;">Support is provided by an educational grant from Vertex Pharmaceuticals.</em>&nbsp;

Asset Subtitle

Moderator(s): Itunu Owoyemi

Presentation(s):

Introduction - Itunu Owoyemi
Rationale, Logistics, and Implications of Screening for AMKD - Barry Freedman
Current Clinical Trials and Design Considerations in Novel AMKD Therapies - Titilayo Ilori

Support is provided by an educational grant from Vertex Pharmaceuticals.

Meta Tag

Pathway(s) Glomerular Diseases

Pathway(s) CKD Non-Dialysis

Session Type ES - Educational Symposium

Speaker(s) Itunu Owoyemi

Speaker(s) Barry Freedman

Speaker(s) Titilayo Ilori

Keywords

APOL1-mediated kidney disease

genotyping

African ancestry

chronic kidney disease

FSGS

living kidney donors

clinical trials

proteinuria

eGFR

AMKD

screening

novel therapies

renal disease

logistics

implications

Barry Freedman

Itunu Owoyemi